{
    "clinical_study": {
        "@rank": "99002", 
        "arm_group": [
            {
                "arm_group_label": "Phase I: Metastatic Breast Cancer Cohort", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Phase I: Metastatic Gastric Cancer Cohort", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Phase II: Kadcyla + capecitabine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Phase II: Kadcyla", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This multicenter study will assess the maximum tolerated dose of capecitabine in combination\n      with Kadcyla (trastuzumab emtansine) in patients with HER2-positive metastatic breast cancer\n      or locally advanced or metastatic gastric cancer using a Phase I design, followed by a\n      randomized, open-label Phase II study to explore the efficacy and safety of the combination\n      of Kadcyla and capecitabine compared with Kadcyla in metastatic breast cancer patients. The\n      anticipated time on study treatment is until disease progression, intolerable toxicity, or\n      withdrawal of consent."
        }, 
        "brief_title": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With Breast Cancer or Gastric Cancer", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer, Gastric Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Metastatic Breast Cancer Patients\n\n          -  ECOG performance status of 0, 1, or 2\n\n          -  Adequate blood cell count\n\n          -  Adequate liver, renal and cardiac function\n\n          -  Histologically or cytologically confirmed breast cancer\n\n          -  Confirmed HER2-positive disease\n\n          -  Metastatic breast cancer with at least one measurable lesion according to RECIST v.\n             1.1\n\n          -  Disease progression on at least one regimen containing trastuzumab and chemotherapy\n\n          -  Patients must have recovered from previous treatments\n\n        Metastatic Gastric Cancer Patients\n\n          -  ECOG performance status of 0, 1, or 2\n\n          -  Adequate blood cell count\n\n          -  Adequate liver, renal and cardiac function\n\n          -  Histologically or cytologically confirmed metastatic gastric cancer or locally\n             advanced gastric cancer\n\n          -  HER2-positive tumor (primary tumor or metastatic lesion)\n\n          -  Inoperable locally advanced or metastatic gastric cancer\n\n        Exclusion Criteria:\n\n          -  Prior treatments before first study treatment:\n\n               1. Investigational therapy within </= 28 days or 5 half lives, whatever is longest\n\n               2. Hormonal therapy within 14 days\n\n               3. Trastuzumab within 21 days\n\n          -  Prior enrollment in a trastuzumab emtansine containing study, regardless of whether\n             the patient received prior trastuzumab emtansine\n\n          -  Prior treatment with capecitabine\n\n          -  History of severe and unexpected reactions to fluoropyrimidine or with known\n             hypersensitivity to fluorouracil\n\n          -  Related capecitabine contraindications\n\n          -  History of intolerance or hypersensitivity to trastuzumab or murine proteins or any\n             product component\n\n          -  History of exposure to cumulative doses of anthracyclines:\n\n          -  Brain metastases that are symptomatic, or require any radiation, surgery, or steroid\n             therapy to control their symptoms within 28 days of first study drug administration\n\n          -  Current peripheral neuropathy of Grade >/= 3 per the National Cancer Institute Common\n             Terminology Criteria for Adverse Events (NCI CTCAE), v4.0\n\n          -  History of other malignancy within the last 5 years, except for appropriately treated\n             carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer,\n             or other cancers with a similar outcome as those mentioned above\n\n          -  Current unstable ventricular arrhythmia requiring treatment\n\n          -  History of symptomatic congestive heart failure (CHF) (New York Heart Association\n             [NYHA] Classes II-IV)\n\n          -  History of myocardial infarction or unstable angina within 6 months prior to first\n             study drug administration\n\n          -  History of a decrease in LVEF to < 40% or symptomatic CHF with previous trastuzumab\n             treatment\n\n          -  Severe dyspnea at rest due to complications of advanced malignancy or requiring\n             current continuous oxygen therapy\n\n          -  Clinically significant malabsorption syndrome or inability to take oral medication\n\n          -  Current severe, uncontrolled systemic disease (e.g., clinically significant\n             cardiovascular, pulmonary, or metabolic disease)\n\n          -  Major surgical procedure or significant traumatic injury within 28 days before\n             enrollment or anticipation of the need for major surgery during the course of study\n             treatment\n\n          -  Current known active infection with HIV, hepatitis B, and/or hepatitis C virus\n\n          -  Lapatinib within 14 days prior to first study drug administration\n\n          -  No signs or symptoms of dihydropyrimidine dehydrogenase (DPD) deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702558", 
            "org_study_id": "MO28230", 
            "secondary_id": "2012-001547-46"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phase I: Metastatic Breast Cancer Cohort", 
                "description": "3.6 mg/kg intravenously every 3 weeks until disease progression, intolerable toxicity, withdrawal of consent", 
                "intervention_name": "trastuzumab emtansine [Kadcyla]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase I: Metastatic Gastric Cancer Cohort", 
                "description": "2.4 mg/kg intravenously every 3 weeks until disease progression, intolerable toxicity, withdrawal of consent", 
                "intervention_name": "trastuzumab emtansine [Kadcyla]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase I: Metastatic Breast Cancer Cohort", 
                    "Phase I: Metastatic Gastric Cancer Cohort"
                ], 
                "description": "650-750 mg/m2 twice daily", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase II: Kadcyla + capecitabine", 
                    "Phase II: Kadcyla"
                ], 
                "description": "3.6 mg/kg intravenously every 3 weeks", 
                "intervention_name": "trastuzumab emtansine [Kadcyla]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Phase II: Kadcyla + capecitabine", 
                "description": "Dosed at maximum tolerated dose (MTD) established in Phase I", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trastuzumab", 
                "Capecitabine", 
                "Fluorouracil", 
                "Maytansine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75231"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "France", 
                "Spain"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "PHASE I STUDY OF THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND CAPECITABINE IN HER2-POSITIVE METASTATIC BREAST CANCER AND HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER PATIENTS FOLLOWED BY A RANDOMIZED, OPEN-LABEL PHASE II STUDY OF T-DM1 AND CAPECITABINE VERSUS T-DM1 ALONE IN HER2-POSITIVE METASTATIC BREAST CANCER", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: MO28230 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Phase I: Maximum tolerated dose (MTD) of the combination of Kadcyla and capecitabine", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702558"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Phase I - Pharmacokinetics: Serum concentration of trastuzumab emtansine", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase I - Pharmacokinetics: Serum concentration of trastuzumab", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase I - Pharmacokinetics: Plasma concentration of DM1", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase I - Pharmacokinetics: Plasma concentration of capecitabine", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase I - Pharmacokinetics: Plasma concentration of 5-fluorouracil", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase I - Safety: incidence of adverse events of the combination of Kadcyla and capecitabine", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase I: Overall response rate according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II - Safety: incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Time to response according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Duration of response according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Time to progression according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Time to treatment failure according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Progression free survival according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Clinical benefit rate according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Phase II: Overall survival according to RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}